Bleeding risk of Quartz Head Laser Ablation for the Prostate Using 980-nm Laser in Patients With Ongoing Platelet Aggregation Inhibition and Oral Anticoagulation

Bleeding risk of Quartz Head Laser Ablation for the Prostate Using 980-nm Laser in Patients With Ongoing Platelet Aggregation Inhibition and Oral Anticoagulation - Bleeding risk of Quartz Head Laser Ablation for the prostate Using 980-nm Laser

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035380

Enrollment

Registered

2018-12-27

Start date

2019-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hypertrophy

Interventions

None listed

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. >50 years old 2. prostate volume >30cc 3. Meet the criteria for the surgery according to "Clinical Guidelines for Male Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia" 2017

Exclusion criteria

Exclusion criteria: 1. Prostate cancer 2. Unable to provide informed consent

Design outcomes

Primary

Measure	Time frame
The rate of postoperative hematuria leading to urethral catheter obstruction.	—

Countries

Japan

Contacts

Public ContactNobuyuki Tanaka Tanaka

Keio University School of Medicine Department of Urology

urotanaka@a2.keio.jp03-5363-3825

Outcome results